- 18 Downloads
Industry funding of research is the greatest known systematic threat to the objectivity of medical research. This paper clarifies the nature and scope of industry funding bias and attempts to quantify it. It reviews four kinds of remedy for industry bias suggested so far: disclosure, standards and regulation, steps towards independence for all clinical research, and case by case assessments, finding most of them helpful but not sufficient. The paper proposes two possible further interventions to reduce the effects of industry bias: qualitative and quantitative discounting of industry results.
- Angell, M. (2005). The truth about the drug companies: How they deceive us and what to do about it (Rev a updated). New York: Random House Trade Paperbacks.Google Scholar
- Gıtzsche, P. C. (2013). Deadly medicines and organised crime: How big pharma has corrupted healthcare. London: Radcliffe Publishing.Google Scholar
- Krimsky, S. (2003). Science in the private interest: Has the lure of profits corrupted biomedical research? Lanham: Rowman & Littlefield Publishers.Google Scholar
- Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O. A., & Bero, L. (2012). Industry sponsorship and research outcome. The Cochrane Database of Systematic Reviews, 12, MR000033.Google Scholar
- Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017). Industry sponsorship and research outcome. The Cochrane Database of Systematic Reviews, 2, MR000033.Google Scholar
- Schott, G., Pachl, H., Limbach, U., Gundert-Remy, U., Ludwig, W. D., & Lieb, K. (2010). The financing of drug trials by pharmaceutical companies and its consequences. Part 1: A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Arzteblatt International, 107(16), 279–285.Google Scholar